Rochester,NY 9/2/2009 11:05:25 PM
ACADIA Pharmaceuticals, Inc. ACAD, pimavanserin study did not meet endpoint
ACADIA Pharmaceuticals, Inc.
Acadia Pharmaceuticals Inc. said that the first pivotal Phase III trial of pimavanserin in patients with Parkinson's disease psychosis, or PDP, did not meet its primary endpoint of antipsychotic efficacy.
Pimavanserin met the key secondary endpoint of motoric tolerability. "We will thoroughly analyze these data along with the data on other secondary and exploratory endpoints over the next month to better understand the outcome of this study. Meanwhile we are continuing with the second Phase III PDP trial with pimavanserin." said CEO Uli Hacksell. Biovail is co-developing pimavanserin for neurological and psychiatric indications in the United States and Canada
About Stock Einstein
StockEinstein uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance. We utilize not only software, but time tested criteria to uncover these potential winners. When these benchmarks are reached or exceeded, our subscribers are immediately notified.
This service is free and available only to subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
Disclaimer: Full disclaimer at http://StockEinsteain.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinsteain, nor any of its affiliates are registered investment advisors or broker dealers.
